» Articles » PMID: 37122358

Effects of Combined Application of Fibroblast Growth Factor (FGF)-2 and Carbonate Apatite for Tissue Regeneration in a Beagle Dog Model of One-wall Periodontal Defect

Overview
Journal Regen Ther
Date 2023 May 1
PMID 37122358
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: There has been an increasing desire for the development of predictive periodontal regenerative therapy for severe periodontitis. In this study, we investigated the effect of the combined use of fibroblast growth factor-2 (FGF-2), a drug for periodontal regeneration approved in Japan, and carbonated apatite (COAp), bioresorbable and osteoconductive scaffold, on periodontal regeneration in beagle dog model of one-wall periodontal defect (severe intraosseous defect) for 24 weeks in comparison with COAp or vehicle alone.

Methods: One-wall periodontal defects were created (mesiodistal width × depth: 4 × 4 mm) on the mesial portion of the mandibular first molar (M1) of beagle dogs on both side. Mixture of FGF-2 and COAp, vehicle and COAp, or vehicle alone were administered to the defects and designated as groups FGF-2+COAp, COAp, and control, respectively. To assess the periodontal regeneration, radiographic analysis over time for 24 weeks, and micro computed tomography (μCT) and histological evaluation at 6 and 24 weeks were performed.

Results: For the regenerated tissue in the defect site, the mineral content of the FGF-2+COAp group was higher than that of the COAp group in the radiographic analysis at 6-24 weeks. In the context of new bone formation and replacement, the FGF-2+COAp group exhibited significantly greater new bone volume and smaller COAp volume than the COAp group in the μCT analysis at 6 and 24 weeks. Furthermore, the density of the new bone in the FGF-2+COAp group at 24 weeks was similar to those in the control and COAp groups. Histological evaluation revealed that the length of the new periodontal ligament and cementum in the FGF-2+COAp group was greater than that in the COAp group at 6 weeks. We also examined the effect of the combined use of the FGF-2 and COAp on the existing bone adjacent to the defect and demonstrated that the existing bone height and volume in the FGF-2+COAp group remained significantly greater than those in the COAp group.

Conclusion: This study demonstrated that the combination of FGF-2 and COAp was effective not only in enhancing new bone formation and replacing scaffold but also in maintaining the existing bone adjacent to the defect site in a beagle dog model of one-wall periodontal defect. Additionally, new periodontal tissues induced by FGF-2 and COAp may follow a maturation process similar to that formed by spontaneous healing. This suggests that the combined use of FGF-2 and COAp would promote periodontal regeneration in severe bony defects of periodontitis patient.

Citing Articles

Engineering soft-hard tissue interfaces in dental and craniofacial system by spatially controlled bioactivities.

Jeong H, Hoang L, Chen N, Zhu E, Wang A, Chen B Bioact Mater. 2024; 45:246-256.

PMID: 39659726 PMC: 11629151. DOI: 10.1016/j.bioactmat.2024.11.030.


Latest update on the use of recombinant growth factors for periodontal regeneration: existing evidence and clinical applications.

Khehra A, Shiba T, Chen C, Kim D Ther Adv Chronic Dis. 2024; 15:20406223241302707.

PMID: 39619169 PMC: 11605760. DOI: 10.1177/20406223241302707.


Combined Effects of Fibroblast Growth Factor-2 and Carbonate Apatite Granules on Periodontal Healing: An In Vivo and In Vitro Study.

Miyata N, Mori S, Murakami T, Bizenjima T, Seshima F, Imamura K Biomedicines. 2024; 12(8).

PMID: 39200129 PMC: 11352071. DOI: 10.3390/biomedicines12081664.


Advancing Dentistry through Bioprinting: Personalization of Oral Tissues.

Shopova D, Mihaylova A, Yaneva A, Bakova D J Funct Biomater. 2023; 14(10).

PMID: 37888196 PMC: 10607235. DOI: 10.3390/jfb14100530.

References
1.
Murakami S, Takayama S, Ikezawa K, Shimabukuro Y, Kitamura M, Nozaki T . Regeneration of periodontal tissues by basic fibroblast growth factor. J Periodontal Res. 2000; 34(7):425-30. DOI: 10.1111/j.1600-0765.1999.tb02277.x. View

2.
Kitamura M, Akamatsu M, Kawanami M, Furuichi Y, Fujii T, Mori M . Randomized Placebo-Controlled and Controlled Non-Inferiority Phase III Trials Comparing Trafermin, a Recombinant Human Fibroblast Growth Factor 2, and Enamel Matrix Derivative in Periodontal Regeneration in Intrabony Defects. J Bone Miner Res. 2015; 31(4):806-14. DOI: 10.1002/jbmr.2738. View

3.
Nakamura T, Hanada K, Tamura M, Shibanushi T, Nigi H, Tagawa M . Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology. 1995; 136(3):1276-84. DOI: 10.1210/endo.136.3.7867582. View

4.
Ishikawa K, Miyamoto Y, Tsuchiya A, Hayashi K, Tsuru K, Ohe G . Physical and Histological Comparison of Hydroxyapatite, Carbonate Apatite, and β-Tricalcium Phosphate Bone Substitutes. Materials (Basel). 2018; 11(10). PMC: 6213161. DOI: 10.3390/ma11101993. View

5.
Okumura M, Okuda T, Nakamura T, Yajima M . Acceleration of wound healing in diabetic mice by basic fibroblast growth factor. Biol Pharm Bull. 1996; 19(4):530-5. DOI: 10.1248/bpb.19.530. View